Oli
Australian medtech startup building a wireless wearable for predictive maternal and fetal monitoring during labor, formerly known as Baymatob.
Sydney, Australia
~A$13M private + >A$9.5M non-dilutive grants
What They Do
Oli makes a wireless wearable that simultaneously captures maternal and fetal signals across roughly 10 biosensors during labor, without interrupting movement or the natural progression of birth. Its patented technology translates raw inputs into live clinical signals and aims to analyze up to 15 pregnancy and birth conditions, flagging patterns that precede postpartum hemorrhage, fetal distress, and stillbirth risk. The product targets the intrapartum monitoring gap left by decades-old cardiotocography.
Competitive Position
Most maternal-fetal monitoring activity sits in antepartum remote monitoring or NICU bedside devices. Oli's intrapartum, multi-signal predictive wearable is a relatively differentiated niche. US adoption is gated on pivotal trial readouts and FDA clearance, so near-term traction is Australia-first.
Funding Rounds
Q2 2026: AUD-denominated round. A$6.5M ≈ US$4.2M at approximately 0.645 AUD/USD at time of announcement. Formerly known as Baymatob. Total private capital ~A$13M plus >A$9.5M non-dilutive grants.